Bedano et al. conducted a phase II trial that studied the efficacy and safety of the combination of erlotinib (EGFR inhibitor) and bevacizumab (VEGFR inhibitor) on pretreated patients with progressive TET (eleven thymomas and seven TC) [17]. The gene discussed is EGFR; the disease is thymoma.